Research records indexed for Retatrutide
This page carries 12 of the 194 records that the literature query returned for Retatrutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 182 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Retatrutide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial pmid:42250575 | 2026 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Blood Glucose; Fatty Acids; Peptides; Hypoglycemic Agents. |
| Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials pmid:41090431 | 2026 | methods-article | other | Not stated | Indexed as methods-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Osteoarthritis, Knee; Sleep Apnea, Obstructive; Obesity; Fatty Acids; Peptides. |
| Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease pmid:41160422 | 2026 | Clinical Trial Protocol, research-article | other | Not stated | Indexed as clinical trial protocol, research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Obesity; Fatty Acids; Peptides; Hypoglycemic Agents. |
| Inotropic effects of retatrutide in isolated human atrial preparations pmid:40613938 | 2026 | research-article | other | Not stated | Indexed as research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Heart Atria; Fatty Acids; Peptides; Cyclic AMP; Cardiotonic Agents. |
| The First Triple Agonist for Antiobesity: Retatrutide pmid:39724554 | 2026 | Review | other | Not stated | Indexed as review. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Weight Loss; Fatty Acids; Peptides; Anti-Obesity Agents. |
| Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models pmid:41741376 | 2026 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice, Inbred C57bl". subject headings: Liver; Mice, Inbred C57BL; Mesocricetus; Mice, Obese; Fatty Liver. |
| The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities pmid:41545327 | 2026 | Review | other | Not stated | Indexed as review. study model from MeSH "Animals" with no rodent species heading. subject headings: Cardiovascular Diseases; Obesity; Gastric Inhibitory Polypeptide; Fatty Acids; Peptides. |
| Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats pmid:40699363 | 2026 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Rats". subject headings: Rats, Sprague-Dawley; Ethanol; Gastric Inhibitory Polypeptide; Fatty Acids; Peptides. |
| Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial pmid:40609566 | 2025 | Clinical Trial, Phase II, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase ii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Diabetes Mellitus, Type 2; Fatty Acids; Peptides; Recombinant Fusion Proteins; Hypoglycemic Agents. |
| Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP pmid:39868848 | 2025 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice". subject headings: Cell Line, Tumor; Obesity; Fatty Acids; Peptides; Adaptor Proteins, Signal Transducing. |
| Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice pmid:39212900 | 2025 | Comparative Study | rodent | Not stated | Indexed as comparative study. study model from MeSH "Mice, Inbred C57bl". subject headings: Kidney; Mice, Inbred C57BL; Diabetic Nephropathies; Diabetes Mellitus, Experimental; Blood Glucose. |
| Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids pmid:40726454 | 2025 | Clinical Trial, Phase II, research-article | human trial | Not stated | Indexed as clinical trial, phase ii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Peptide Hormones; Fatty Acids; Triglycerides. |
Where this page sits
Compound page: Retatrutide. Class: Incretin receptor agonists.
Retrieved 2026-10-10.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:retatrutide
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med (2023). pmid:37366315
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (2023). pmid:37385280
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med (2024). pmid:38858523
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol (2025). pmid:40609566
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol (2024). pmid:38367045
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.